![Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d763732d-acff-446e-872e-e81d6e44f06f/gr1_lrg.jpg)
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine
![The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3188c36b-9a69-4509-9116-c8797795272b/gr1.gif)
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet
![Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic - Advances in Radiation Oncology Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic - Advances in Radiation Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7590baad-dcc7-4154-b171-aabee1c16daa/gr2_lrg.jpg)
Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic - Advances in Radiation Oncology
![Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial - The Lancet Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3bf08982-433a-4e78-933c-d49e6ac25024/gr1_lrg.jpg)
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial - The Lancet
![Four Phase Clinical Trials Process With Time | Presentation Graphics | Presentation PowerPoint Example | Slide Templates Four Phase Clinical Trials Process With Time | Presentation Graphics | Presentation PowerPoint Example | Slide Templates](https://www.slideteam.net/media/catalog/product/cache/1280x720/f/o/four_phase_clinical_trials_process_with_time_slide01.jpg)
Four Phase Clinical Trials Process With Time | Presentation Graphics | Presentation PowerPoint Example | Slide Templates
Analysis of COVID-19 clinical trials: A data-driven, ontology-based, and natural language processing approach | PLOS ONE
![Formative research to design a culturally-appropriate cancer clinical trial education program to increase participation of African American and Latino communities | BMC Public Health | Full Text Formative research to design a culturally-appropriate cancer clinical trial education program to increase participation of African American and Latino communities | BMC Public Health | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12889-020-08939-4/MediaObjects/12889_2020_8939_Fig1_HTML.png)